Patents by Inventor Jakob Dupont

Jakob Dupont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20230226179
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 4, 2023
    Publication date: July 20, 2023
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20220340653
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 27, 2022
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR, Austin L. Gurney, Ming-Hong Xie
  • Methods and compositions for treatment of cancer
    Patent number: 11339213
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly colorectal, ovarian (e.g., platinum-resistant ovarian), pancreatic, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., leucovorin, 5-fluorouracil, and irinotecan; paclitaxel; gemcitabine and ABRAXANE® (albumin-bound paclitaxel for injectable suspension); and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a colorectal, ovarian, pancreatic, or endometrial tumor.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 24, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar, Robert Joseph Stagg
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11230596
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: January 25, 2022
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • COMBINATION THERAPY FOR TREATMENT OF DISEASE
    Publication number: 20210403553
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: May 26, 2021
    Publication date: December 30, 2021
    Inventors: Christopher Lamond Murriel, Timothy Charles Hoey, Austin L. Gurney, Julie Michelle Roda, Minu K. Srivastava, Inkyung Park, Jakob Dupont
  • Methods for treatment of cancer comprising TIGIT-binding agents
    Patent number: 11136384
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Grant
    Filed: December 11, 2020
    Date of Patent: October 5, 2021
    Assignee: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob Dupont, Hema Parmar
  • Combination therapy for treatment of disease
    Patent number: 11046760
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: June 29, 2021
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Christopher Lamond Murriel, Timothy Charles Hoey, Austin L. Gurney, Julie Michelle Roda, Minu K. Srivastava, Inkyung Park, Jakob Dupont
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20210101971
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20210052728
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: May 13, 2020
    Publication date: February 25, 2021
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20190284269
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: November 30, 2017
    Publication date: September 19, 2019
    Inventors: Jakob DUPONT, Hema PARMAR
  • METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER
    Publication number: 20190023776
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly pancreatic, colorectal, and endometrial cancers. Also provided are methods, compositions, and kits for treatment of tumors or cancer using combinations that include a VEGF/DLL4 bispecific agent and one or more chemotherapeutic agents (e.g., gemcitabine and ABRAXANE®; leucovorin, 5-fluorouracil, and irinotecan; and paclitaxel and carboplatin). The present invention further provides methods of using the agents or combinations of agents to inhibit growth of a pancreatic, colorectal, or endometrial tumor. Also described are methods of treating cancer, particularly pancreatic, colorectal, and endometrial cancer, comprising administering a therapeutically effect amount of an agent, antibody, or therapeutic combination of the present invention to a patient having a tumor or cancer.
    Type: Application
    Filed: September 23, 2016
    Publication date: January 24, 2019
    Inventors: Jakob DUPONT, Hema PARMAR, Robert Joseph STAGG
  • Methods and Monitoring of Treatment with a WNT Pathway Inhibitor
    Publication number: 20190000970
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Application
    Filed: April 25, 2018
    Publication date: January 3, 2019
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob DUPONT, Robert J. STAGG
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20180344847
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: August 9, 2018
    Publication date: December 6, 2018
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Combination Therapy For Treatment Of Disease
    Publication number: 20180273618
    Abstract: The present invention provides methods comprising combination therapy for modulating immune responses, for inhibiting tumor growth, and/or for treating cancer. In particular, the present invention provides Notch pathway inhibitors in combination with immunotherapeutic agents for the treatment of cancer and other diseases.
    Type: Application
    Filed: February 6, 2018
    Publication date: September 27, 2018
    Inventors: Christopher Lamond MURRIEL, Timothy Charles HOEY, Austin L. GURNEY, Julie Michelle RODA, Minu K. SRIVASTAVA, Inkyung PARK, Jakob DUPONT
  • Methods and monitoring of treatment with a WNT pathway inhibitor
    Patent number: 9987357
    Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: June 5, 2018
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Jakob Dupont, Robert J. Stagg
  • Methods and Monitoring of Treatment With A DLL4 Antagonist
    Publication number: 20170299598
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Application
    Filed: February 1, 2017
    Publication date: October 19, 2017
    Inventors: Steven Eugene BENNER, Robert Joseph Stagg, Jakob Dupont
  • TREATMENT OF GASTRIC CANCER
    Publication number: 20170157245
    Abstract: The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer, particularly gastric cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit growth of a gastric tumor. Also described are methods of treating gastric cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a gastric tumor or gastric cancer.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 8, 2017
    Inventor: Jakob DUPONT
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER
    Publication number: 20170143826
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 25, 2017
    Applicant: Genentech, Inc.
    Inventors: Jakob Dupont, Cornelia Irl, Amreen Husain, Mika A. Sovak, Jing Yi, Hoa Nguyen
  • Methods and monitoring of treatment with a DLL4 antagonist
    Patent number: 9599620
    Abstract: Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Steven Eugene Benner, Robert Joseph Stagg, Jakob Dupont
  • METHODS FOR TREATING CANCER WITH NOTCH1 ANTIBOIDES
    Publication number: 20170022289
    Abstract: The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of an anti-Notch 1 antibody.
    Type: Application
    Filed: March 4, 2015
    Publication date: January 26, 2017
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Jakob Dupont, Ann M. Kapoun, Belinda Cancilla